Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 31;20(1):81.
doi: 10.1186/s12944-021-01508-7.

Association between inflammatory markers and serum paraoxonase and arylesterase activities in the general population: a cross-sectional study

Christa Meisinger  1   2 , Dennis Freuer  3   4 , Achim Bub  5 , Jakob Linseisen  3   4
Affiliations

Association between inflammatory markers and serum paraoxonase and arylesterase activities in the general population: a cross-sectional study

Christa Meisinger et al. Lipids Health Dis. .

Abstract

Background: Recent studies focused on modulating factors of paraoxonase-1 (PON1) activity. In some studies the association between pro-inflammatory markers and PON1 activity was examined, but so far no population-based investigations on this issue have been conducted. The present study investigated the relationships between the pro-inflammatory markers tumor necrosis factor (TNF)-α, leptin, interleukin (IL)-6, and high-sensitive C-reactive protein (hs-CRP) and paraoxonase and arylesterase, two hydrolytic activities of PON1, in the population-based Bavarian Food Consumption Survey II.

Methods: Based on 504 participants (217 men, 287 women), the relationship between the pro-inflammatory markers and the outcomes paraoxonase and arylesterase activities were investigated using multivariable linear models.

Results: Circulating plasma levels of leptin (P-value < 0.0001), hs-CRP (P-value = 0.031) and IL-6 (P-value = 0.045) were significantly non-linearly associated with arylesterase activity. Leptin levels were also significantly associated with paraoxonase activity (P-value = 0.024) independently from confounding factors, including high-density lipoprotein (HDL) cholesterol. With increasing levels of these inflammatory parameters, arylesterase and paraoxonase activities increased; however, at higher levels (> 75th percentile) the activities reached a plateau or even decreased somewhat. After Bonferroni-Holm correction, only leptin remained non-linearly but significantly associated with arylesterase activity (adjusted overall P-value < 0.0001). Neither age nor sex nor obesity modified the associations. No association was found between TNF-α and paraoxonase or arylesterase activity.

Conclusions: The present findings suggest that in persons with very high levels of inflammation, PON1 activity may be impaired, a fact that might subsequently be accompanied by a higher risk for cardiometabolic diseases. Whether or not the measurement of PON1 activity in combination with a lipid profile and certain inflammatory markers could improve the prediction of cardiometabolic diseases in middle-aged individuals from the general population should be evaluated in clinical studies.

Keywords: Arylesterase activity; Inflammation; Oxidative stress; PON1; Paraoxonase activity.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Non-linear associations between leptin, hs-CRP and IL-6 levels and paraoxonase as well as arylesterase activities, respectively (total sample). Models were adjusted for age, sex, waist circumference, alcohol consumption, HDL cholesterol, physical activity, socioeconomic status, and smoking status
Fig. 2
Fig. 2
Non-linear associations in the sex-specific subgroup analyses between leptin, hs-CRP and IL-6 levels and paraoxonase as well as arylesterase activities, respectively. Models were adjusted for age, waist circumference, alcohol consumption, HDL cholesterol, physical activity, socioeconomic status, and smoking status
See this image and copyright information in PMC

References

    1. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860–867. doi: 10.1038/nature05485. - DOI - PubMed
    1. Gadde KM, Martin CK, Berthoud HR, Heymsfield SB. Obesity: pathophysiology and management. J Am Coll Cardiol. 2018;71(1):69–84. doi: 10.1016/j.jacc.2017.11.011. - DOI - PMC - PubMed
    1. Hamjane N, Benyahya F, Nourouti NG, Mechita MB, Barakat A. Cardiovascular diseases and metabolic abnormalities associated with obesity: what is the role of inflammatory responses? A systematic review. Microvasc Res. 2020;131:104023. doi: 10.1016/j.mvr.2020.104023. - DOI - PubMed
    1. Zorena K, Jachimowicz-Duda O, Slezak D, Robakowska M, Mrugacz M. Adipokines and obesity. Potential link to metabolic disorders and chronic complications. Int J Mol Sci. 2020;21:3570. doi: 10.3390/ijms21103570. - DOI - PMC - PubMed
    1. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology. 2004;145(5):2273–2282. doi: 10.1210/en.2003-1336. - DOI - PubMed